Photocure ASA: Clinical and cost impact analysis shows beneficial impact of replacing current surgical modalities with Cevira®

Published: 9 November 2017Medical Information
A poster demonstrating the clinical and cost impact of Cevira® was presented at the ISPOR European congress in Glasgow, Scotland, November 4-8, 2017. The budget impact model from a US payer perspective shows beneficial impact of replacing the current surgical modalities, LEEP and cold knife conization, with Cevira®.

Photocure ASA announced today that a poster on the clinical and cost impact of Cevira® from a US payer perspective was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasgow, Scotland, November 4-8, 2017. The results show that Cevira® at a unit price of 2500USD is cost neutral compared to the standard of care surgical methods, loop electrosurgical excision procedure (LEEP) and cold knife conization (CKC), or cost beneficial when the impact of preterm births is taken into consideration.

Link to ISPOR web-site. Poster A26:

These data come from a budget impact model developed from the perspective of a US payer with a base case patient population from 5 million covered lives. The model captured all Medicare costs for cervical cancer screening, diagnosis, treatment and follow-up using 2016 reimbursement rates. Clinical data used in the model were all from peer-reviewed published analyses. A scenario analysis determined the impact of each of the treatment modalities (Cevira®, LEEP, CKC) on preterm births and associated costs.

"This well designed and robust health economic model analysis demonstrates the potential clinical and cost benefits of a non-surgical modality like Cevira® for women with high-grade squamous intraepithelial lesions (HSIL, CIN2/3) of the cervix. The Phase 2b trial showed solid safety and efficacy data, and the convenient and easy-to-use integrated drug-light device was highly appreciated both by the patients and the gynecologists participating in the study", said Professor and Chair, Mark H. Einstein, Department of OB/GYN & Women's Health, Clinical Research Unit, Rutgers New Jersey Medical School.

"It is very encouraging to see that the budget impact model shows Cevira®to be valuable both from a clinical and cost perspective compared to current standard of care in the US. The surgical modalities have increased risk of side effects, including a higher risk of preterm births, and this is an enormous burden on the society. When taking into account direct medical costs over the first year only, the model shows that replacing the surgical methods with Cevira® will reduce costs significantly", commented Kjetil Hestdal, M.D., Ph.D., President and CEO, Photocure ASA.

About Cevira®
Cevira® is a unique, non-invasive photodynamic therapy under development for the treatment of oncogenic human papilloma virus (HPV) infection and pre-cancerous cervical abnormalities.

For further information, please contact:
Kjetil Hestdal
President & CEO
Tel: + 47 913 19 535
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company focusing on urology. Based on its unique proprietary Photocure Technology® platform, Photocure is committed to developing and commercializing highly selective and minimally invasive solutions to improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). More information about Photocure is available at,,

News and events